The coexistence of hidradenitis suppurativa (HS) and acne fulminans (AF) has only recently been reported in the literature. We present a case of a 17-year-old man who presented with a 2 years history of severe acne and HS. He was initially started on oral clindamycin and rifampicin for 3 months with no clinical improvement. Acne lesions became worse with the presence of nodules and necrotic ulcers, while weight loss, low-grade fever, back and knee pain, and psychological distress were noted. We prescribed adalimumab in its standard dosing regimen. Remission of AF was achieved in 3 months, whereas adalimumab has not been as effective in treating the HS lesions. Its dosage was increased to 80 mg weekly and more than 80% clinical improvement of HS lesions was obtained in 2 months. The patient maintained on this dosage till this day and efficacy is sustained. TNF-α inhibitors are considered an effective option in the treatment of HS, while it has been also suggested as a treatment option in AF. Our patient was successfully treated with adalimumab. Since the coexistence of HS and AF has a devastating emotional effect on the patient, there is an urgent need to implement therapeutic approaches.

1.
Gulliver
W
,
Zouboulis
CC
,
Prens
E
,
Jemec
GB
,
Tzellos
T
.
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
.
Rev Endocr Metab Disord
.
2016
;
17
(
3
):
343
51
. .
2.
Greywal
T
,
Zaenglein
AL
,
Baldwin
HE
,
Bhatia
N
,
Chernoff
KA
,
Del Rosso
JQ
, et al.
Evidence-based recommendations for the management of acne fulminans and its variants
.
J Am Acad Dermatol
.
2017
;
77
(
1
):
109
17
. .
3.
Dawoud
NM
,
Elnady
BM
,
Elkhouly
T
,
Yosef
A
.
Adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapy
.
Indian J Dermatol Venereol Leprol
.
2018 Jan–Feb
;
84
(
1
):
104
7
. .
4.
Wieczorek
M
,
Walecka
I
.
Hidradenitis suppurativa - known and unknown disease
.
Reumatologia
.
2018
;
56
(
6
):
337
9
. .
5.
Hosthota
A
,
Bondade
S
,
Basavaraja
V
.
Impact of acne vulgaris on quality of life and self-esteem
.
Cutis
.
2016
;
98
(
2
):
121
4
.
6.
Saternus
R
,
Schwingel
J
,
Müller
CSL
,
Vogt
T
,
Reichrath
J
.
Ancient friends, revisited: systematic review and case report of pyoderma gangrenosum-associated autoinflammatory syndromes
.
J Transl Autoimmun
.
2020
;
3
:
100071
. .
7.
Hessam
S
,
Sand
M
,
Georgas
D
,
Anders
A
,
Bechara
FG
.
Microbial profile and antimicrobial susceptibility of bacteria found in inflammatory hidradenitis suppurativa lesions
.
Skin Pharmacol Physiol
.
2016
;
29
(
3
):
161
7
. .
8.
Zouboulis
CC
,
Hansen
H
,
Caposiena Caro
RD
,
Damiani
G
,
Delorme
I
,
Pascual
JC
, et al.
Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa
.
Dermatology
.
2019
;
18
:
1
6
. .
9.
Miguel
D
,
Tittelbach
J
,
Elsner
P
.
A dramatic case of acne fulminans responding to adalimumab
.
J Dtsch Dermatol Ges
.
2019
;
17
(
8
):
837
8
. .
10.
Duchatelet
S
,
Join-Lambert
O
,
Delage
M
,
Miskinyte
S
,
Guet-Revillet
H
,
Lam
T
, et al.
Remission of chronic acne fulminans and severe hidradenitis suppurativa with targeted antibiotherapy
.
JAAD Case Rep
.
2019
;
5
(
6
):
525
8
. .
11.
Gottlieb
J
,
Madrange
M
,
Gardair
C
,
Sbidian
E
,
Frazier
A
,
Wolkenstein
P
, et al.
PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens
.
Br J Dermatol
.
2019
;
181
(
4
):
866
9
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.